Oncimmune Holdings PLC - Nottingham, England-based immunodiagnostics developer - Announces plans to focus on higher value customers, penetrating key accounts, partnering with key technology suppliers and launching new tools. Intends to accelerate new commercial contracts through partnerships with more contract research organisations to expand customer base, leverage auto-antibody analysis capabilities across new areas like companion diagnostics, and augment its commercial team. Also plans to expand its business models "beyond price-per-sample to more strategic partnership models" with upfront project and milestone success fees to better reflect its value. Update follows the disposal of Oncimmune Ltd in May, and the hiring of Martin Gouldstone as chief executive officer and Martin Hudson as finance director in August and September respectively. Company says final results for year ended August 31 will be released in due course.
Current stock price: 17.46 pence, up 11% on Thursday afternoon in London
12-month change: down 71%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Oncimmune (ONC)